Key Takeaways Boston Scientific's Q3 EPS rose 19% to $0.75, topping estimates and guidance. BSX's quarterly revenues climbed 20.3% to $5.07B, led by strength in Cardiovascular and MedSurgBoston Scientific raised 2025 sales growth to 20% and EPS outlook to $3.02-$3.04. Boston Scientific Corporation (BSX) posted third-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 19% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 5.6% and exceeded the company’s adjusted EPS guidance ...